Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Monthly Archives: March 2012
UCLA scientists find insulin, nutrition prevent blood stem cell differentiation in fruit flies
Posted: Published on March 12th, 2012
Public release date: 11-Mar-2012 [ | E-mail | Share ] Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Health Sciences UCLA stem cell researchers have shown that insulin and nutrition keep blood stem cells from differentiating into mature blood cells in Drosophila, the common fruit fly, a finding that has implications for studying inflammatory response and blood development in response to dietary changes in humans. Keeping blood stem cells, or progenitor cells, from differentiating into blood cells is important as they are needed to create the blood supply for the adult fruit fly. The study found that the blood stem cells are receiving systemic signals from insulin and nutritional factors, in this case essential amino acids, that helped them to maintain their "stemness," said study senior author Utpal Banerjee, professor and chairman of the molecular, cell and developmental biology department in Life Sciences and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine at UCLA. "We expect that this study will promote further investigation of possible direct signal sensing mechanisms by mammalian blood stem cells," Banerjee said. "Such studies will probably yield insights into chronic inflammation and the myeloid cell accumulation seen in patients … Continue reading
Posted in Mesenchymal Stem Cells
Comments Off on UCLA scientists find insulin, nutrition prevent blood stem cell differentiation in fruit flies
Insulin, Nutrition Prevent Blood Stem Cell Differentiation in Fruit Flies
Posted: Published on March 12th, 2012
Newswise UCLA stem cell researchers have shown that insulin and nutrition keep blood stem cells from differentiating into mature blood cells in Drosophila, the common fruit fly, a finding that has implications for studying inflammatory response and blood development in response to dietary changes in humans. Keeping blood stem cells, or progenitor cells, from differentiating into blood cells is important as they are needed to create the blood supply for the adult fruit fly. The study found that the blood stem cells are receiving systemic signals from insulin and nutritional factors, in this case essential amino acids, that helped them to maintain their stemness, said study senior author Utpal Banerjee, professor and chairman of the molecular, cell and developmental biology department in Life Sciences and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine at UCLA. We expect that this study will promote further investigation of possible direct signal sensing mechanisms by mammalian blood stem cells, Banerjee said. Such studies will probably yield insights into chronic inflammation and the myeloid cell accumulation seen in patients with type II diabetes and other metabolic disorders. The study appears March 11, 2012 in the peer-reviewed journal Nature Cell Biology. In … Continue reading
Posted in Mesenchymal Stem Cells
Comments Off on Insulin, Nutrition Prevent Blood Stem Cell Differentiation in Fruit Flies
International Stem Cell Corporation Completes $5 Million Financing and Elects Jim Berglund to the Board of Directors
Posted: Published on March 12th, 2012
CARLSBAD, Calif.--(BUSINESS WIRE)-- International Stem Cell Corporation (OTCBB:ISCO.OB - News) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic, cosmetic and research products, announced today that it had obtained new capital financing and made important changes in the composition of its Board of Directors to ensure that Independent Directors hold the majority of Board seats. The financing consists of $5 million in newly issued Series G Convertible Preferred Stock (without warrants), convertible into Common Stock at a conversion price of $0.40/share, the market price of the Companys Common Stock on the date the offer to purchase was made. This financing was made by AR Partners LLC, a healthcare investment firm owned by Dr. Andrey Semechkin, ISCOs CEO and Co-Chairman of the Board of Directors. Concurrently with the closing of this financing, the Company elected to its Board of Directors Dr. James Berglund, co-founder of Enterprise Partners Venture Capital - one of the premier venture capital firms in the field of healthcare technology founded in 1985. Dr. Berglund, with his extensive professional experience, continues as an active participant in the biotech and healthcare industries. Dr. Berglund will replace Kenneth C. Aldrich, co-founder and former CEO of the Company during the period 2008-2009, … Continue reading
Posted in Mesenchymal Stem Cells
Comments Off on International Stem Cell Corporation Completes $5 Million Financing and Elects Jim Berglund to the Board of Directors
Biostem U.S., Corporation Appoints Heart Surgeon, Thomas W. Prendergast, M.D. to Its Scientific and Medical Board of …
Posted: Published on March 12th, 2012
CLEARWATER, FL--(Marketwire -03/12/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of cardiothoracic surgeon Thomas W. Prendergast, M.D. to its Scientific and Medical Board of Advisors (SAMBA). Biostem CEO, Dwight Brunoehler stated, "The Company is now positioned for growth and international expansion. Adding a world class team of clinical, laboratory, and regulatory experts for our Scientific and Medical Board of Advisors to guide our pursuits is essential. Dr. Prendergast brings a wealth of experience not only in the scientific aspects of stem cell use in regenerative medicine, but also in forging research and international economic development opportunities." Dr. Prendergast is a busy clinical cardiothoracic surgeon, who performs 200-250 open-heart operations and 5 to 15 heart transplants each year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair. He is presently Director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active … Continue reading
Posted in Mesenchymal Stem Cells
Comments Off on Biostem U.S., Corporation Appoints Heart Surgeon, Thomas W. Prendergast, M.D. to Its Scientific and Medical Board of …
JCI early table of contents for March 12, 2012
Posted: Published on March 12th, 2012
Public release date: 12-Mar-2012 [ | E-mail | Share ] Contact: Sarah Jackson press_releases@the-jci.org 919-684-0620 Journal of Clinical Investigation EDITOR'S PICK Restoring what's lost: uncovering how liver tissue regenerates The liver is unique among mammalian organs in its ability to regenerate after significant tissue damage or even partial surgical removal. Laurie DeLeve and her colleagues at the University of Southern California in Los Angeles wanted to better understand which cells are specifically responsible for driving liver regeneration. A specialized cell type, known as liver sinusoidal endothelial cells, has generally been thought to promote regeneration of liver tissue. However, the DeLeve team suspected that stem cells and progenitor cells, which have the capacity to differentiate into mature cell types, might be responsible for stimulating liver regeneration by generating hepatocyte growth factor. Using a rat model system, they first identified the presence of stem and progenitor cells that give rise to liver sinusoidal endothelial cells in both the liver and the bone marrow. They next sought to determine which population of stem and progenitor cells are required for regeneration. DeLeve and colleagues found that the bone marrow-derived cells were not required for liver cell proliferation in the absence of damage. In contrast, … Continue reading
Posted in Mesenchymal Stem Cells
Comments Off on JCI early table of contents for March 12, 2012
AVI BioPharma Announces Late-Breaker Oral Presentation of Phase IIb DMD Study at 2012 AAN Annual Meeting in April
Posted: Published on March 12th, 2012
SOURCE: AVI BioPharma, Inc. BOTHELL, WA--(Marketwire - Mar 12, 2012) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that an abstract describing the Company's Phase IIb study evaluating eteplirsen for the treatment of Duchenne Muscular Dystrophy has been accepted as part of the American Academy of Neurology (AAN) Emerging Science program (formerly known as the Late-Breaking Science program). The brief oral presentation will take place during AAN's 64th Annual Meeting in New Orleans, LA at the Ernest N. Morial Convention Center from April 21 to April 28, 2012. AAN describes Emerging Science Abstracts as works of major scientific importance and representing scientific advances that emerged after the original October 2011 abstract deadline that warrant expedited presentation and publication. AVI's abstract does not contain study results, but a description of the study design and type of findings to be presented at the meeting. "The results of this study represent an important milestone for the development of treatments for Duchenne Muscular Dystrophy and we are pleased that AAN agreed to include this first placebo-controlled study evaluating exon skipping in DMD as one of the 15 Emerging Science Abstracts for the conference this year," said Chris Garabedian, president … Continue reading
Posted in Muscular Dystrophy Treatment
Comments Off on AVI BioPharma Announces Late-Breaker Oral Presentation of Phase IIb DMD Study at 2012 AAN Annual Meeting in April
Upsher-Smith Presents Data Highlighting Topiramate Extended-Release Formulation at 100th Annual APhA Meeting
Posted: Published on March 12th, 2012
MAPLE GROVE, Minn., March 12, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (http://www.upsher-smith.com) today presented Phase I pharmacokinetic data evaluating the profiles of 10 internally developed once-daily, extended-release formulations of the epilepsy medication topiramate. Of the formulations investigated, one extended-release (ER) formulation of topiramate emerged as being optimal for further development by meeting all pre-established single-dose and simulated steady-state goals as compared with immediate-release (IR) topiramate (Topamax) administered to healthy volunteers. These findings led to the further development of USL255, an investigational treatment for the management of epilepsy in adults. USL255 is currently the subject of a global Phase III clinical trial (PREVAIL). Information about the trial can be found at: http://clinicaltrials.gov/ct2/show/NCT01142193?term=upsher+smith&rank=4. The poster was presented on Saturday, March 10, at the American Pharmacists Associations' (APhA) 2012 Annual Meeting in New Orleans, LA (http://www.aphameeting.org). "With the identification of an optimal formulation of extended-release topiramate, we hope to reduce the blood level fluctuations that can occur when taking immediate-release topiramate and that may be associated with adverse events at peak levels and break-through seizures at trough levels," said Mark Halvorsen, Pharm.D., Senior Director, Clinical Development at Upsher-Smith. The abstract of this poster is available in the March/April edition of the Journal of … Continue reading
Comments Off on Upsher-Smith Presents Data Highlighting Topiramate Extended-Release Formulation at 100th Annual APhA Meeting
Autism Speaks Panel and Lecture at BPL
Posted: Published on March 12th, 2012
By Anonymous Mar. 12, 2012 On Wednesday evening, March 14, the New England Area of Autism Speaks will host the first ever Autism Science Panel Lecture at the Rabb Lecture Hall in the Boston Public Library. This event is free and open to the public and will give parents and caretakers direct access to some of the brightest minds in autism research and treatment. The Lecture will include scientists in the fields of genetics, treatment, translational research, and alternative interventions. One in 110 children (one in 70 boys) are annually diagnosed with autism. As science continues to make great strides in autism research and development, parents are often left to navigate this disorder largely on there own. Greater Boston parents will have a chance to hear and learn from scientists and experts in the autism field.What: Autism Panel for Parents, Caretakers and General Public When: Wednesday, March 14 -- 7pm to 9pm Where: Boston Public LibrarySponsored by: Autism Speaks The panel will consist of the following researchers who are all leaders in their field:Dr. Randy Carpenter Seaside Therapeutics speaking on Translational ResearchDr. Guoping Feng MIT speaking on GeneticsDr. Chris McDougle Lurie Center for Autism speaking on treatment in autismOur moderator … Continue reading
Comments Off on Autism Speaks Panel and Lecture at BPL
Your Health: Picturing Parkinson's
Posted: Published on March 12th, 2012
By:Ivanhoe Broadcast News To view our videos, you need to enable JavaScript. Learn how. install Adobe Flash 9 or above. Install now. Then come back here and refresh the page. Nilou Salimpour Media Relations Cedars-Sinai Medical Center (310) 292-6536 salimpourn@cshs. org If Parkinson's disease is left untreated, it can completely disable an individual. It may also lead to a deterioration of all brain functions and an early death. The exact cause of Parkinson's disease is still unknown. It has yet to be discovered why some brain cells waste away, but there are some potential factors that may play a role. Parkinson's disease occurs when the nerve cells, which make dopamine in the brain, are slowly destroyed. Without dopamine, the nerve cells in that part of the brain cannot properly send messages. This leads to the loss of muscle function. Other factors that may contribute to Parkinson's disease are genetic mutations, being exposed to certain toxins or viruses, low norepinephrine levels or having lewy bodies-unusual protein clumps which are found in the brain. There is no cure for Parkinson's disease. The goal of treatment is to control the symptoms, mostly by increasing the levels of dopamine in the brain, making the … Continue reading
Posted in Parkinson's Treatment
Comments Off on Your Health: Picturing Parkinson's
Allon advances Parkinson's disease program
Posted: Published on March 12th, 2012
VANCOUVER , March 12, 2012 /CNW/ - Allon Therapeutics Inc. (TSX: NPC.TO - News) announced today the completion of its first phase of work in a preclinical Parkinson's disease (PD) model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation (MJFF) for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles (UCLA). The first phase of the project conducted experiments on young alpha-synuclein transgenic animals, a model for PD. Feedback from a recent review by MJFF scientists and an expert panel of scientific reviewers helped strengthen the study design of the second phase of the project, studying the effect of davunetide on aged transgenic animals with pronounced motor impairment and dopaminergic deterioration, similar to what is seen in mild-to-moderate PD patients. Allon expects the results of these studies to be released in conjunction with publications or presentation at an international meeting at a later date. The objective of this work is centred on using relevant preclinical models to determine if there is a strong scientific rationale for moving davunetide into clinical trials in PD. In assessing the clinical potential of davunetide in PD, … Continue reading
Posted in Parkinson's Treatment
Comments Off on Allon advances Parkinson's disease program